Moderna: plans to cut costs by E1bn in 2025

(CercleFinance.com) - Moderna announces commercial updates and progress in its pipeline of mRNA-based drugs.


For example, the laboratory has shared positive immunogenicity data for its combination influenza vaccine and COVID, and launched a Phase 3 efficacy study (P304) for its seasonal influenza vaccine (mRNA-1010), with efficacy results expected in 2025.

Moderna says it enters 2025 with a priority portfolio focused on respiratory viruses, rare diseases, oncology, as well as latent viruses.

In 2024, we achieved product sales of between $3bn and $3.1bn, reduced our operating costs by more than 25% compared with 2023, and aim to reduce them by $1bn in 2025, with a plan for $500m in additional savings in 2026, Moderna said.

We remain focused on our three strategic priorities: driving sales growth, securing up to 10 product approvals over the next three years, and reducing costs across our business, he added.

Moderna now expects revenues of $1.5bn to $2.5bn in 2025, mainly in H2, primarily driven by sales of Spikevax and mRESVIA vaccines. The company expects to end 2025 with cash and investments of around $6bn.


Copyright (c) 2025 CercleFinance.com. All rights reserved.